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Development of a structural epitope mimic: an idiotypic
approach to HCV vaccine design
Vanessa M. Cowton 1, Ania M. Owsianka1, Valeria Fadda 2, Ana Maria Ortega-Prieto 3, Sarah J. Cole1, Jane A. Potter2,
Jessica K. Skelton3, Nathan Jeffrey1, Caterina Di Lorenzo1, Marcus Dorner3,4, Garry L. Taylor2 and Arvind H. Patel 1✉
HCV vaccine development is stymied by the high genetic diversity of the virus and the variability of the envelope glycoproteins.
One strategy to overcome this is to identify conserved, functionally important regions—such as the epitopes of broadly neutralizing
antibodies (bNAbs)—and use these as a basis for structure-based vaccine design. Here, we report an anti-idiotype approach that
has generated an antibody that mimics a highly conserved neutralizing epitope on HCV E2. Crucially, a mutagenesis screen was
used to identify the antibody, designated B2.1 A, whose binding characteristics to the bNAb AP33 closely resemble those of the
original antigen. Protein crystallography confirmed that B2.1 A is a structural mimic of the AP33 epitope. When used as an
immunogen B2.1 A induced antibodies that recognized the same epitope and E2 residues as AP33 and most importantly protected
against HCV challenge in a mouse model.
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INTRODUCTION
There is an urgent need for a vaccine to prevent infection with
hepatitis C virus (HCV). Over 70 million people are chronically
infected with the virus1. Effective drugs are now available to treat
chronic infections2–4 but we still lack a prophylactic vaccine to
prevent primary infection.
A minority of newly-infected individuals (10–40%), clear HCV
infection, but the majority develop a chronic infection5,6.
Successful clearance of virus correlates with a broad, strong
T-cell response and rapid induction of neutralizing antibodies
during the early phase of infection7,8. Importantly, the rate of
spontaneous clearance in individuals who have previously cleared
the virus increases to about 80% upon reinfection, showing that a
protective immune response has been induced, indicating that
vaccination is a realistic strategy9,10.
The high genetic diversity of the virus—which exists as seven
distinct genotypes and over 60 subtypes—makes it difficult to
create a single vaccine that will protect against all infections10,11.
Another obstacle is the presence of immunodominant, hypervari-
able regions within the envelope glycoproteins12,13 which direct
the immune response towards non-neutralizing antibody produc-
tion. The challenge is to create a vaccine that directs the immune
response to conserved, functionally important regions, which
typically are poorly immunogenic14,15.
Much work has been done to identify and characterize
antibodies that can neutralize a broad range of HCV isolates by
binding to conserved sites of vulnerability on the virus16,17. Most
broadly-neutralizing antibodies (bNAbs) bind to the E2 glycopro-
tein and block its interaction with the CD81 receptor18. AP33 is
one of several bNAbs that bind to a highly conserved region of E2
(residues 412–423)19,20. AP33 potently neutralizes all genotypes of
HCV in vitro19,21–23. It protected mice from HCV infection when
passively administered24. HCV1, a bNAb which binds to the same
epitope, prevented HCV infection in chimpanzees25 and reduced
allograft rejection after liver transplantation in human trials26,27.
A molecule able to elicit antibodies similar to AP33/HCV1 would
therefore be an attractive vaccine candidate.
The most obvious such molecule would be a peptide
corresponding to E2412–423. We and others tried this, as soon as
E2412–423 was identified as the linear epitope of several bNAbs, but
immunization with the peptide coupled to KLH never resulted in
any antibodies that recognized E228. The failure of the peptide to
elicit an anti-E2 response was not surprising, because a peptide is
flexible and does not necessarily adopt the same shape as a
conformationally constrained section of protein, despite having
the same amino acid sequence. Structural studies were then
carried out to determine the shape adopted by the peptide when
complexed with the bNAbs, with a view to constraining it in
a conformation that would elicit the desired antibodies. X-ray
crystallography revealed that the peptide, and, by implication, the
E2412–423 epitope, adopts three distinct conformations: the most
potent bNAbs AP33 and HCV1 bind to a β-hairpin structure29–31,
bNAb 3/11 binds to a double-turn structure while bNAbs HC33.1,
HC33.4 and HC33.8 bind to a more open, single-turn structure32,33.
We attempted to stabilize the β-hairpin conformation recognized
by AP33 by making a cyclic peptide immunogen34. Immunization
with the cyclic peptide did elicit antibodies, but further analysis
showed that these antibodies bound a different conformation of
the E2 peptide, they had low affinity for E2 and they failed to
neutralize HCV.
Here we describe an alternative strategy to create a molecule
that will generate AP33-like antibodies. We use AP33 as a template
to make a structural mimic of its antigen-binding site (paratope),
by exploiting the ability of the immune system to generate
antibodies that are specific for the paratope of another antibody.
Jernes’ idiotype network theory postulates that the immune
system generates a cascade of antibodies that interact with each
other35,36. Initial exposure to an antigen induces the production of
antibodies against it, termed Ab1. The unique paratope is
recognized as a set of idiotypic epitopes, or idiotopes, by the
immune system. Anti-idiotype (anti-Id) antibodies generated
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against the Ab1 are termed Ab2. A subset of these, called Ab2ß,
complement the paratope of the Ab1 precisely enough to
effectively mimic the structure of its epitope on the original
antigen. An Ab2ß antibody can be used as a surrogate antigen to
elicit Ab3 antibodies, and a subset of these, termed Ab1′, bind to
the original antigen37. There are several other classes of anti-Id
antibodies that do not mimic the antigen, such as Ab2γ, which
recognize part of the Ab1 paratope. Distinguishing Ab2ß from
Ab2γ can be difficult, because both these classes inhibit the
binding of Ab1 to antigen. Numerous studies have demonstrated
that Ab2ß anti-Id antibodies can function as vaccines to elicit a
protective immune response against infectious pathogens and
against tumor-associated antigens38–41. Traditional vaccine
approaches have failed for highly variable viruses such as HCV
and HIV. Both fields are now focusing on the conserved epitopes
of bNAbs as leads for vaccine design42–45. Here we have used the
anti-Id approach to make a molecular structural mimic of the
E2412–423 epitope on HCV E2. We applied a mutagenic strategy to
identify a specific Ab2ß, B2.1 A, which requires the same binding
residues for interaction with AP33 as the viral antigen. We
demonstrate that immunization with B2.1 A induces Ab1′ anti-
bodies that protect against viral challenge.
RESULTS
Production and characterization of Ab2 antibodies
The broadly neutralizing antibody AP33 was selected as an Ab1 as
it has proven to be a potent neutralizing antibody that can protect
against HCV infection. Analysis of all sequences deposited in the
NCBI database using the HCV-GLUE platform46 showed that the
AP33 epitope is conserved in 93% of HCV E2 sequences
(Supplementary Table 1). Only 7% of sequences contain a mutation
of one of the contact residues (L413, N415, G418, W420) or an
N417S/T mutation that shifts the glycosylation site to N415, any of
which disrupt binding21,29,47.
Mouse monoclonal antibodies to AP33 were produced and
screened by ELISA to identify those that could (i) bind to
biotinylated AP33 and (ii) block binding of AP33 to HCV E2
glycoprotein. These anti-idiotype antibodies are rare; in total, we
screened approximately 5000 primary hybridoma cell clones from
19 fusion events to obtain 122 that secreted anti-idiotype (Ab2)
antibodies. All the Ab2 antibodies were able to inhibit the binding
of MAb AP33 to E2 therefore it is likely that they recognize
determinants within, or close to, the AP33 antigen-binding site
(Fig. 1a). They had no effect on the interaction between E2 and
MAb 3/11, which binds to a different conformation of the same
E2412–423 epitope
21,29,30,32 (Fig. 1b).
Rather than test all the Ab2s in mice, molecular techniques were
used to identify Ab2ß antibodies. Nucleotide sequencing showed
that there was no similarity between the Ab2 complementarity
determining regions (CDRs) and the E2412–423 epitope. Never-
theless, sequencing was useful in that it identified duplicates,
which were excluded from further analysis. Ultimately, there were
18 unique anti-Id clones. All the Ab2s only bound to intact AP33
and not AP33 light chain or a hybrid antibody comprising AP33
heavy chain and an irrelevant κ light chain, suggesting that
perhaps they were all Ab2ßs48.
Using a combined structure- and mutagenesis-based approach,
we previously showed that the residues located in the central part
of the antigen-binding pocket are essential for binding of AP33 to
E229 (Supplementary Fig. 1). A panel of mutant AP33 antibodies, in
which each of the residues comprising the antigen-binding pocket
was replaced by alanine, proved crucial here for fine characteriza-
tion of the Ab2s.
The panel was used to determine the “fit” of the Ab2s into the
AP33 antigen-binding pocket. We found that AP33 binding of 14
of the Ab2s was severely reduced (>60%) by one or more
mutations, indicating that they recognized determinants within
the AP33 antigen-binding pocket. In contrast, the binding of some
Ab2s was not affected by any mutation, indicating that they
recognized determinants outside the antigen-binding pocket. The
Ab2s could be ranked according to how closely their binding
profile resembled that of E2, and this analysis revealed that only
one Ab2, designated B2.1 A, was affected by exactly the same
mutations as E2 (Table 1). We thus identified B2.1 A as an Ab2ß
that mimics the E2412–423 epitope.
Molecular basis of antigenic mimicry
To verify that B2.1 A is a genuine mimic of the E2412–423 epitope, a
Fab fragment of AP33 was co-crystallized in complex with a single-
chain variable fragment (scFv) of B2.1 A, and the structure
determined to a resolution of 1.8 Å. The structure unambiguously
shows the positions of all the amino acid side-chains and of water
molecules at the interface between the two antibodies. The
asymmetric unit of this Ab1-Ab2 complex was composed of one
molecule of AP33 Fab and one molecule of B2.1 A scFv.
Comparison of this Ab1-Ab2 complex with the Ab1-Ag complex
(ie AP33 in complex with a peptide corresponding to its E2
epitope (29; pdb accession codes 4gag, 4gaj)) shows that B2.1 A
docks into the AP33 antigen-binding site (Supplementary Figs. 2
and 3). CDR-H3 of B2.1 A complemented by water molecules
mimics the shape and character of the E2 epitope, even though
there is no sequence similarity. In general, there is a conservation
of the side chain character of the peptide residues critical for the
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Fig. 1 Ab2 antibodies specifically inhibit binding of AP33 to HCV E2. Binding to E2 of (a) biotinylated AP33 and (b) biotinylated 3/11 in the
presence of six Ab2s (A164, B2.1 A, B4.1 F, K391, L1.1 A, P1.52) and an isotype control, ALP98. The values shown are the means of three
independent ELISAs. All SDs were within 8% of the mean, and are not shown for the sake of clarity.
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AP33–E2 interaction. B2.1 A mimics the shape of the antigen
particularly around the critical E2 residue W420, which is deeply
buried in the Ab1-Ag complex. The hydrophobicity of W420 is
conferred by several aromatic residues in B2.1 A while W420 itself
is mimicked by FH98 of B2.1 A in the Ab1-Ab2 complex resulting in
the loss of the hydrogen bond (Fig. 2, Supplementary Table 2). The
other important E2 residues at the Ab1–Ag interface are G418,
N415, and L413. The shape of the antigen around G418 is
preserved by the side chain of B2.1 A YH100A, which forms
extensive contacts with WL96 of AP33. The polar character of E2
residue N415, which is deeply buried in the Ab1–Ag complex, is
conferred by the sidechain hydroxyl of YH100A of B2.1 A, which
also provides a hydrogen bond to YH50 of AP33 (Supplementary
Tables 2 and 3). Interestingly, the interactions of L413 with AP33
are mimicked not by an amino acid residue but by five water
molecules in the Ab1–Ab2 complex (Fig. 2). Importantly, this
mimicry is also functional with one of the water molecules
forming a hydrogen bond to AP33 VHY-100 and bridges to VHY-31
in B2.1 A. Solvent-mediated mimicry has been observed previously
at the interface of antigen–antibody complexes helping to
overcome imperfections in shape complementarity49.
This structural analysis confirms that B2.1 A is an Ab2ß, i.e., an
anti-Id antibody that fits into the antigen-binding site of AP33
precisely enough to provide a complementary surface of it,
thereby, to effectively mimic the structure of the original antigen.
Surface Plasmon Resonance (SPR) was used to directly compare
the binding affinity for AP33 of soluble E2 that lacks the
transmembrane domain (E2661) and B2.1 A Fab. The binding
kinetics of the two molecules were very similar (Fig. 3). The
average association rate constants (ka) for B2.1 A Fab and E2661
were 9.73 and 16.0 × 104 M−1 s−1, respectively, and their
respective dissociation rate constants (kd) were 3.64 and 5.42 ×
10−4 s−1. Thus B2.1 A Fab had slightly slower rates of association
and dissociation than E2661, resulting in almost identical
equilibrium dissociation constants (KD) of 3.76 nM for B2.1 A Fab
and 3.4 nM for E2661. These measurements show that AP33 binds
to B2.1 A as strongly as it binds to its authentic antigen, E2.
We did not expect B2.1 A to be a perfect mimic of the E2412–423
epitope, and therefore used the structural information, together
with protein–protein interaction prediction servers to guide the
design of mutations aimed at improving the complementarity of
the molecular interface (Supplementary Table 4). However,
somewhat disappointingly, all the mutations disrupted the
AP33–B2.1 A interaction. Only two mutants VHF98W and VHN100G
retained some binding, albeit weaker than WT, while the
Table 1. Binding properties of E2 and of Ab2 antibodies to wild type and mutant AP33.
Relative strength of binding (%)a
AP33 light chain mutantsb AP33 heavy chain mutantsb
Y28 N30 F32 N91 N92 V93 D94 W96 Y33 Y50 Y53 Y58 I95 T97 Y100
E2 112 89 −4 7 60 79 74 −0.4 3 −1 100 0.7 10 101 5
Ab2
B2.1 A 82 73 21 36 36 49 41 1 10 4 68 5 29 89 8
L1.1 A 5 88 3 85 83 88 86 1 26 9 85 9 26 84 13
P1.T 20 88 54 18 48 72 50 4 67 15 90 13 15 86 11
L1.2 A 76 90 52 31 63 83 88 1 30 24 88 9 41 86 54
A16A 93 92 64 57 66 82 70 7 15 35 46 40 63 75 10
K391 112 74 45 66 82 77 82 14 91 37 82 41 35 98 54
A53M 80 85 55 21 86 77 89 11 94 88 104 59 54 98 17
2K55 87 69 23 81 83 84 88 1 50 27 77 61 60 92 89
2K49 21 93 43 94 105 94 97 70 29 90 88 91 84 93 25
K201 79 90 68 89 115 96 90 3 55 34 79 67 57 104 82
2K56 89 84 61 88 90 86 94 1 57 39 74 67 66 90 83
B4.1 F 79 95 49 75 78 100 92 10 76 79 94 62 74 97 57
A5 90 98 53 98 105 98 100 4 81 54 89 71 74 98 88
2K19 96 88 75 90 94 88 97 2 72 54 79 73 75 96 88
A1.5 82 98 94 94 100 96 98 55 93 86 69 85 65 96 78
A164 60 100 66 83 106 98 106 70 73 68 65 93 72 95 59
2K160 78 100 82 86 82 90 104 96 90 91 80 94 91 97 75
P1.52 96 103 79 95 105 106 107 64 84 79 102 71 89 94 80
aBinding of E2 and Ab2s to AP33 mutants in ELISA, as a percentage of binding to WT AP33. Each value is the mean of three replicate assays. Alanine
substitutions that reduced binding by at least 60% are in bold typeface.
bMutants named according to the identity and position of the amino acid in the WT sequence; e.g., Y28, tyrosine at position 28 of the light chain. Each residue
was changed to alanine.
Fig. 2 Antigen mimicry by B2.1 A. a Ab1–Ab2 complex (AP33
heavy chain: orange, light chain: yellow; B2.1 A heavy chain: blue,
light chain: pink) and b Ab1–Ag complex (AP33 heavy chain:orange,
light chain:yellow; peptide:cyan; pdb accession code 4gag). Water
molecules are shown as magenta spheres.
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remaining mutations ablated the interaction altogether (Supple-
mentary Fig. 4). The reasons for this are not clear, although the
protein–protein interaction prediction servers did predict that the
mutations based on the structure would disrupt binding. It is
possible that our alanine-scanning selection process (Table 1) has
selected an Ab2ß that binds AP33 similarly to the AP33:E1E2
interaction thus explaining the analogous binding affinities. Given
that B2.1 A already has such a high affinity for AP33, perhaps it is
not surprising that we could not increase it by altering any of the
amino acid residues within the binding site.
Immunization with B2.1 A elicits Ab1′ antibodies that recognize
HCV E2
To test whether B2.1 A could elicit AP33-like antibodies, Balb/c
mice were immunized with B2.1 A conjugated to KLH. All the
immune sera (a) strongly inhibited binding of AP33 to B2.1 A
(Fig. 4a), showing that they contained B2.1A-specific antibodies,
and (b) reacted specifically with HCV E2 (Fig. 4b). Given that the
constant region of the B2.1 A antibody was unlikely to play any
useful antigenic role, we tested whether the Fab fragment or the
scFv of B2.1 A, both conjugated to KLH, could elicit the same
response as the whole IgG. Immunization with B2.1 A Fab resulted
in a higher average anti-E2 titer (700) than immunization with
B2.1 A IgG (500), but the difference is not statistically significant
due to the small number of animals used and the wide range of
titers obtained (Fig. 4b). Immunization with the scFv was less
successful, with only two out of six mice producing any E2-specific
antibodies. Most of the immune sera also contained a high titer
(>5000) of antibodies directed against B2.1 A and KLH, so we
attempted to focus the immune response on E2 by giving
alternate boosters with a peptide corresponding to E2411–424 after
a primary immunization with B2.1 A Fab-KLH. This resulted in a
slightly higher average anti-E2 titer (800) than that obtained by
boosting with B2.1 A Fab-KLH, but the difference between the two
boosting regimens is not statistically significant (Fig. 4b). We and
others had already established that a peptide corresponding to
E2411–424 conjugated to KLH did not elicit E2-specific antibodies,
so we did not repeat this experiment here. It is significant that we
consistently detected E2-specific Ab1′ antibodies in all Balb/c mice
immunized with B2.1 A or B2.1 A Fab. We also found that Rosa26-
Fluc mice immunized with B2.1 AFab-KLH had a strong immune
response, with E2-specific Ab1′ titers above 10000 in most mice
(Supplementary Fig. 5).
Fig. 3 Affinity of HCV E2661 and B2.1 A Fab for AP33. SPR sensorgrams showing the binding to and subsequent dissociation from
immobilized AP33 of (a) monomeric E2661 and (b) B2.1 A Fab at five concentrations (5 nM to 80 nM). Biacore X100 Evaluation software was
used to obtain kinetic affinity constants by fitting a 1:1 binding model (dashed black lines). The kinetic constants shown are the mean and SD
of three independent experiments.
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Fig. 4 B2.1 A elicits Ab1′ antibodies that recognize HCV E2. a Sera of mice immunized with B2.1A-KLH were tested at 1:300 dilution for
blocking of biotinylated AP33–B2.1 A interaction. Values shown are the mean and SD of three ELISAs. b Balb/c mice were given a primary
immunization of B2.1 A IgG, B2.1 A Fab, or B2.1 A scFv followed by five boosters of the same antigen, or a primary immunization of B2.1 A Fab
followed by alternate boosters of B2.1 A Fab and E2411–424 peptide. The anti-E2 titer of immune sera collected nine days after the last booster
was measured by ELISA. Each symbol represents one animal and the horizontal lines indicate the geometric mean of each group; significant
differences from the control group are indicated (*p < 0.05).
V.M. Cowton et al.
4
npj Vaccines (2021)     7 Published in partnership with the Sealy Institute for Vaccine Sciences
Immunization with B2.1A elicits Ab1′ antibodies that bind to the
E2412–423 epitope
Competition ELISA showed that Ab1′-E2 binding was reduced in a
concentration-dependent manner by a peptide corresponding to
the E2412–423 epitope, whereas an identical peptide containing a
W420R mutation had no effect (Fig. 5a) indicating that all the
E2-specific Ab1′ antibodies in the Ab3 sera recognized W420, an
essential contact residue for AP3321,29. As expected, MAb ALP98,
which binds to a different linear epitope on E2, was not affected
by either of the peptides.
Direct ELISA using a panel of E2 mutants, in which each
residue in turn across the E2412–423 epitope was replaced by
alanine, showed that the binding profile of the Ab1′ antibodies
in the Ab3 sera was very similar to that of AP33. E2 binding of
the Ab1′ antibodies was abrogated by substitution of L413,
N415, G418, or W420, the residues critical for AP33 and HCV1
binding. Additionally, Ab1′-E2 binding was reduced by alanine
substitution of I414, T416, and H421 (Fig. 5b). As expected, the
binding of ALP98 was not affected by any of the substitutions
(Fig. 5b).
Immunization with B2.1 A protects against HCV challenge in vivo
Our data show compellingly that Ab1′ antibodies raised by
immunization with B2.1 A have similar properties to AP33;
therefore, we would expect them to neutralize HCV. The serum
concentrations of Ab1′ antibodies were not high enough to
convincingly neutralize HCVcc, but, when concentrated by affinity-
purification, the Ab1′ antibodies efficiently neutralized G451R
HCVcc virus (HCVG451R) at 2 µg/ml and with an IC50 about twice
that of AP33 (Supplementary Figures 7a and b, respectively).
Encouraged by these preliminary in vitro data, we put all our effort
into demonstrating in vivo protection. Rosa26-Fluc mice, which
provide a model system for testing HCV entry in vivo, were
immunized with B2.1 A Fab and produced a strong E2-specific
immune response (Supplementary Fig. 5), but technical difficulties
prevented us from challenging the immunized mice with HCVcc-
Cre. Instead, a humanized liver chimeric mouse model was used to
assess whether Ab1′ antibodies could protect against HCV
challenge. Ab1′-containing IgG was purified from sera collected
from mice immunized with B2.1A-Fab and control IgG was purified
from mock-immunized mice. FNRG mice engrafted with human
hepatocytes were dosed with IgG at day −1, 0, and +1 and
challenged with HCV on day 0: either with Gt1b virus (BiCre-Con1),
or with Gt2a virus (BiCre-JC1). HCV virus titers were determined at
day 7, 21, and 35 post-challenge. The animals that were given
Ab1′ IgG were completely protected from infection with the Gt1b
virus whereas those given control IgG had peak titers of 1 × 105
TCID50/ml (Fig. 6a). In a parallel experiment, the Ab1′ IgG gave
only partial protection from challenge with Gt2a virus, but even
so, there was a 2-log difference in virus titer between the control
IgG- and the Ab1′ IgG-treated animals at day 7. Over time, this
difference decreased and by day 35 the titers of Gt2a virus were
similar (Fig. 6b). In a follow-up experiment, the mice that were
protected from the Gt1b HCV infection were re-challenged after
the Ab1′ IgG had cleared from their systems. This time all mice
succumbed to infection with Gt1b HCV, reaching similar titers to
the original control IgG-treated group, thereby confirming that
these animals were susceptible to HCV infection (Fig. 6c).
DISCUSSION
The great variability of viruses such as HIV, influenza, and HCV
allows them to evade the immune system in natural infection, and
frustrates the development of effective vaccines. Broadly neu-
tralizing antibodies are powerful tools that help to address this
Fig. 5 Alanine scanning and peptide competition shows that Ab1′ antibodies bind to the same epitope as AP33. A representative
Ab3 serum (1:300 dilution) was (a) pre-incubated with E2412–423 WT peptide (solid) or with a W420R mutant sequence (open symbols), and
then tested by ELISA for binding to E2661, (b) tested for binding to a panel of E2 mutants, in which each residue in turn from 412 to 424 was
replaced by alanine, MAbs AP33, and ALP98 served as positive and negative controls, respectively. Values shown are the mean and SD of three
ELISAs. Very similar results were obtained with other Ab3 sera.
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Fig. 6 B2.1 A protects against HCV challenge. HCV titers from
human liver chimeric mice injected with control IgG or Ab1′ IgG and
infected with (a) BiCreCon1 (Gt1b), (b) BiCreJC1 (Gt2a), (c) HCV titers
from Ab1′ IgG-treated mice shown in (a) following reinfection with
BiCreCon1. The number of mice in each group is shown in brackets.
Values shown are the mean and SEM.
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problem, because they can be used to identify conserved sites of
vulnerability on the virus. In theory, the epitopes of bNAbs provide
a basis for the design of vaccines that confer broad protection. In
practice, it is highly challenging to make an immunogen based on
a conserved epitope that represents only a small portion of a viral
protein. More often than not, the epitopes of bNAbs are
conformational, i.e. they comprise two or more exposed loops
that are adjacent in the folded protein but distant from each other
in the linear sequence, so it is difficult to create an antigen that
represents the epitope. Even when an epitope is linear, a peptide
corresponding to the sequence often does not elicit the desired
immune response, probably because it does not adopt the correct
conformation and therefore does not adequately mimic the native
protein—as in the case of E2412–423. To circumvent this problem,
we revisited the anti-idiotype network theory35. We selected a
well-characterized bNAb, AP33, and used it as template to reverse-
engineer a surrogate immunogen, B2.1 A, that mimics the
antigenic structure of a highly conserved epitope, but is
structurally unrelated to the viral protein.
To investigate the extent to which B2.1 A truly mimics the E2
epitope, we obtained a high-resolution structure of the Ab1–Ab2
complex, and compared it to the Ab1–Ag complex29. It was
interesting to see how the CDR3 of B2.1 A mimics the shape and
character of the E2412–423 epitope in its β-hairpin conformation
without having any sequence similarity. There are in fact very few
cases where both the Ab1–Ab2 structure and the Ab1–Ag
structure are available at high resolution. A series of papers
investigated the structural basis for mimicry of two anti-idiotype
antibodies, E225 and E5.2, which bind to a lysozyme-binding
antibody, D1.350–52. E225, which binds D1.3 with lower affinity,
was found not to be a structural mimic. In contrast, E5.2 and
lysozyme, which both bind D1.3 with similar affinities, share 13
contact residues, indicating that E5.2 is a good structural mimic for
lysozyme. More recently, Wong and co-workers identified the anti-
idiotype Fab E1 to be a partial structural mimic for Dengue virus E
protein53. These studies support the idea of structural mimicry,
which originated purely from the observed binding properties of
antibodies35,36. Our strategy for characterizing the Ab2s was based
on the premise that a structural mimic of an epitope would
contact the same residues on the Ab1 as the original antigen. This
proved to be true, and the analysis, using a panel of AP33
mutants, resulted in the selection of a bona fide structural mimic.
We demonstrated that B2.1 A was an effective immunogen,
completely protecting against HCV Gt1 infection and giving partial
protection against HCV Gt2. This result is contrary to the sensitivity
to neutralization of these viruses in vitro with AP33. In vitro Gt1b
(BiCre-Con1) virus is poorly neutralized by AP33 whereas Gt2a
(BiCre-JC1) is much more sensitive (Supplementary Fig. 6) to AP33
neutralization. The protection against Gt2 waned over time;
however, it is not clear whether this was due to viral escape or,
because protection was not sterilizing, a lack of a functioning
immune system in the mice allowed viral load to increase as Ab1′
IgG decreased over time. Notably, reports have shown that Gt2a
(Jc1) virus passaged in the presence of AP33 generates resistant
mutants whereas Gt1b (Con1) does not, suggesting the sensitivity
observed in vivo is more likely due to viral escape47,54. This is the
first report of an anti-idiotypic approach for HCV; we show that
this technique has potential to aid vaccine development for
viruses where traditional methods have failed. Selection of both
the Ab1 i.e. a bNAb and Ab2, a structural antigen mimic, are used
to focus the immune system to recognize important broadly
neutralizing epitopes. In order to further develop B2.1 A Fab
towards a human vaccine there is potential for further modifica-
tions, for example, to humanize the scaffold regions to remove
xenotypic epitopes. Another area we are exploring is coupling
the Fab to a nanoparticle structure such as ferritin or lumazine
synthase which have been used to create multimeric vaccine
molecules55,56
The E2412–423 epitope is conserved in over 90% of all known
HCV sequences, but a vaccine that elicits bNAbs to this epitope
alone would likely not be sufficient to protect from HCV. It has
been shown that when HCV is grown in the presence of AP33, viral
escape mutants arise that are resistant to antibody neutraliza-
tion47 although more recent analysis suggests that such mutants
have reduced fitness54. Therefore, we envisage that an immuno-
gen such as B2.1 A would be used in combination with molecules
targeting one or more other conserved B-cell epitopes, to elicit
bNAbs with different specificities that could act in concert. Such a
structure-based B-cell vaccine would ideally be combined with a
T-cell vaccine, in order to elicit cellular immunity as well as
protective antibodies.
METHODS
Cells
Human epithelial kidney cells (HEK)-293T (ATCC CRL-1573), Sp2/0-Ag 14
myeloma cells (ATCC CRL-1581), human hepatoma Huh-7, Huh7.5, and
Huh7-J20 were grown in Dulbecco’s modified Eagle’s medium (GIBCO)
supplemented with 10% fetal calf serum (FCS), non-essential amino acids
(GIBCO), and penicillin/streptomycin. AP33 and B2.1 A hybridoma cells
were grown in the same medium supplemented with 10% ultra-low IgG
FCS in CELLine CL350 bioreactors (Thermofisher) according to the
manufacturer’s instructions. Baby hamster kidney (BHK-21) cells (ATCC
CCL-10) were grown in Glasgow minimal essential Eagle’s medium
supplemented with 10% newborn calf serum, 4% tryptose phosphate
broth, and penicillin/streptomycin. Spodoptera frugiperda (Sf9) cells were
grown in TC-100 medium (GIBCO) supplemented with penicillin/strepto-
mycin and 10% FCS. Hi Five™ Trichoplusia ni cells (BTI-TN-5B1-4) were
grown in Express Five™ serum-free medium supplemented with 16mM
L-glutamine. Mammalian cells were incubated at 37 °C in 5% CO2, insect
cells at 28 °C.
Antibodies
The anti-E2 murine MAbs AP33 and ALP98, and the rat MAb 3/11 have
been described previously57–59. The anti-idiotype murine MAb B2.1 A was
generated as described herein. MAbs were purified from hybridoma
supernatant on HiTrap protein G columns using an Äkta Purifier (GE
Healthcare). Fab fragments of AP33 and B2.1 A were made by digesting the
respective IgGs for 7 h with immobilized papain, followed by purification
using a Nab protein A Plus column (Thermofisher). AP33 Fab was further
purified for crystallization by anion exchange on Mono Q 5/50 GL (GE
Healthcare) in 20mM Tris pH 8.5, using a gradient of 0–300mM NaCl.
Biotinylation was carried out using the ImmunoprobeTM biotinylation kit
(Sigma, BK101). B2.1 A Fab was purified for surface plasmon resonance
(SPR) by size exclusion chromatography (SEC) on Superdex 200 GL (GE
Healthcare).
HCV E2661
The sequence encoding amino acid residues (aa) 384–661 of HCV
genotype 1a strain H77c (GenBank accession no. AF009606), plus an
N-terminal 6-histidine tag, was inserted into the pAcGP67-A transfer vector
(BD Biosciences). Sf9 cells were co-transfected with the transfer vector and
Baculogold™ linearized baculovirus DNA, to make recombinant baculovirus
(rBac) expressing the ectodomain of E2 as a secreted, soluble protein. The
rBac E2661 was cloned by limiting dilution, amplified, and used to infect Hi
Five™ cells at a multiplicity of infection (moi) of 1. After 3 days’ incubation
the supernatant medium was harvested, filtered through a 0.22 µm
membrane, and dialyzed first against 20mM sodium phosphate pH 6.8,
150mM NaCl and subsequently against 20 mM sodium phosphate pH 8.0,
300mM NaCl. Ultrapure imidazole was added to a concentration of 20mM,
and the supernatant loaded onto a HisTrap HP Ni Sepharose column using
an Äkta Purifier (GE Healthcare). E2661 was eluted with a gradient of
40–200mM imidazole in 20mM sodium phosphate pH 8.0, 300mM NaCl,
to separate monomeric molecules from dimers and multimers. Monomeric
E2661 was purified to homogeneity by size exclusion chromatography (SEC)
on a Superdex 200 Increase 10/300 GL column (GE Healthcare).
V.M. Cowton et al.
6
npj Vaccines (2021)     7 Published in partnership with the Sealy Institute for Vaccine Sciences
Production of Ab2 antibodies
Balb/c mice were immunized with AP33 conjugated to Keyhole Limpet
Hemocyanin (KLH). Purified AP33 IgG was conjugated to KLH, in a ratio of
2:1 (wt/wt), using 0.2% glutaraldehyde, and then dialyzed into phosphate-
buffered saline (PBS). A primary subcutaneous (s/c) injection of 15 µg
AP33-KLH emulsified in Complete Freund’s Adjuvant (CFA) was followed by
three s/c injections of 15 µg in Incomplete Freund’s Adjuvant (IFA) at two-
weekly intervals. A week after the last injection, serum samples were tested
for Ab2 antibodies. The mice received a final intraperitoneal injection of
150 µg AP33-KLH in PBS and five days later their spleen cells were fused
with Sp2/0-Ag 14 mouse myeloma cells using 50% PEG. After 12 days of
selection in HAT medium, hybridoma colonies were tested for Ab2
production, and serially diluted to obtain single-cell clones. Ab2 antibodies
were purified by protein G affinity for further characterization.
Detection of Ab2 antibodies
Microtitre plates were coated with goat anti-mouse IgG (H+ L chains)
40mg/ml (Jackson Immuno Research) at a dilution of 1:20000 in PBS.
Mouse IgG was captured from the hybridoma supernatant during a 1 h
incubation at RT. Biotinylated AP33 (b-AP33) was added at 0.1 μg/ml and
incubated at RT for 1 h. Bound b-AP33 was detected with streptavidin-
conjugated to horse radish peroxidase (HRP) (Sigma S2438, 1:20,000)
followed by 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate. Absorbance
was measured at 450 nm.
Competition with AP33
A modified GNA-capture ELISA was used to detect antibodies that
compete with AP33 for binding to E2. Soluble genotype 1a E2 was made
by infecting BHK cells at 5 PFU/cell with recombinant vaccinia virus
expressing aa 384–660 of HCV genotype 1a strain H77c (Owsianka et al
2001). Four days after infection the cells were harvested, washed in PBS
and resuspended in lysis buffer (40 mM Tris pH 7.5, 1 mM EDTA, 150mM
NaCl, 1% Igepal CA-630, 20 mM iodoacetamide and completeTM protease
inhibitor cocktail (Roche). Nuclei were pelleted by centrifugation at
15,000 × g and the cytoplasmic extract containing E2660 stored in aliquots
at −20 °C. Microtitre plates coated with 2.5 µg/ml Galanthus nivalis
agglutinin (GNA) were used to capture E2 glycoproteins from cell lysate.
Hybridoma supernatant medium or purified Ab2s were mixed with b-AP33,
added to the plates and incubated for 1 h at RT. Bound b-AP33 was
detected with streptavidin-conjugated to horse radish peroxidase (HRP)
(Sigma S2438, 1:20,000) followed by 3,3′,5,5′-Tetramethylbenzidine (TMB)
substrate. Absorbance was measured at 450 nm. A decreased signal
indicated blocking by Ab2 antibodies of b-AP33–E2 interaction. To test
whether Ab2s were specific for AP33, b-AP33 was replaced by b-3/11.
Binding of Ab3 sera to E2 alanine-scanning mutants
Plasmids encoding alanine substitution mutants of genotype 1a strain
H77c E1E2 were constructed as previously described20 and used to
transfect HEK-293T cells. After two days’ incubation the cells were washed
in PBS and cytoplasmic extracts prepared as described above. Microtitre
plates coated with 2.5 μg/ml GNA were used to capture E1E2 glycoproteins
from cell lysates. MAbs or Ab3 sera were added and incubated for 1 h at RT.
Bound antibodies were detected with anti-mouse IgG HRP followed by
TMB. Absorbance was measured at 450 nm.
Binding of Ab2 MAbs to AP33 mutants
Wild type (WT) and mutant AP33 MAbs were produced by transient
transfection of HEK cells with expression vectors encoding the appropriate
antibody heavy and light chain combinations as previously described29.
The mutagenesis was carried out on a human-mouse chimera comprising
the variable region of AP33 combined with a human constant region, to
enable testing of interaction with murine Ab2s. To measure the
concentrations of WT and mutant AP33 MAbs, serially diluted IgG-
containing media were added, with an appropriate IgG standard alongside,
to microtitre plates coated with anti-human IgG antibody (Sigma I-9010;
1:10,000). Captured chimeric MAbs were detected with anti-human IgG
HRP (Sigma A-0170; 1:10,000), followed by TMB. Equal amounts of WT and
mutant AP33 MAbs were then captured onto microtitre plates coated with
anti-human IgG antibody. Ab2 MAbs were added at 1 µg/ml and incubated
for 1 h at RT. Bound Ab2 MAbs were detected with anti-mouse IgG HRP
(Sigma A4416; 1:5000) followed by TMB. Absorbance was measured at
450 nm.
Blocking of AP33–B2.1 A interaction by Ab3
Microtitre plates were coated with 1 µg/ml B2.1 A. Dilutions of sera were
mixed with b-AP33, added to the plates, and incubated for 1 h at RT.
Bound b-AP33 was detected with streptavidin-HRP followed by TMB.
Absorbance was measured at 450 nm. A decreased signal indicated
blocking of b-AP33–B2.1 A interaction by competing serum antibodies.
Binding to E2661 and peptide inhibition of binding
Microtitre plates were coated with 1 µg/ml of purified E2661 (genotype 1a
strain H77c). Dilutions of MAbs or sera were added and incubated for 1 h at
RT. To test for peptide inhibition, MAbs or sera were pre-incubated with
peptides for 30mins at RT. Bound antibodies were detected with anti-
mouse IgG HRP followed by TMB. Absorbance was measured at 450 nm.
Titer was defined as the reciprocal of the highest dilution of immune
serum that gave a signal at least three times higher than the average signal
of pre-immune sera at the same dilution.
Binding of B2.1 A mutants to AP33
Microtitre plates were coated with 5 µg/ml of AP33 IgG. Serial dilutions of
WT and mutant MBP-B2.1 A scFv were added and incubated for 1 h at RT.
Binding of MBP-B2.1 A scFv was detected with anti-MBP-HRP (Abcam
49923; 1 µg/ml) followed by TMB. Absorbance was measured at 450 nm.
In all ELISAs, Immulon 2HB microtitre plates were used. The plates were
washed three times between each step in PBS plus 0.05% Tween 20 (PBST).
PBST was used as a diluent at every step except coating, which was done
in PBS. After coating, plates were blocked with 2% skimmed milk in PBST.
Immunization of mice to generate an Ab3 response
Balb/c or Rosa 26-Fluc mice were immunized with Ab2 IgG, or IgG
fragments, conjugated to KLH as above. A primary s/c injection of 50 µg
Ab2-KLH emulsified in CFA was followed by up to five s/c booster
injections of 50 µg antigen in IFA at two-weekly intervals. In some
experiments, the antigen used for alternate booster injections was
E2411–424 peptide (IQLINTNGSWHINS) conjugated to KLH. Serum samples
were taken 7–10 days after the last injection, or after each injection.
To generate Ab1′ IgG for passive transfer into the human chimeric liver
mouse model (see below), Rosa 26-Fluc mice were mock-immunized or
immunized with 50 μg B2.1 A Fab coupled to KLH. Sera was collected and
pooled. The IgG was purified on a HiTrap Protein G column using an
ÄKTA™ Pure chromatography system (GE Healthcare). Fractions were
pooled and dialyzed into PBS.
Cloning, expression, and purification of B2.1 A scFv
The genes encoding the variable heavy (vH) and variable light (vL) chain
were generated by reverse transcription-polymerase chain reaction from
total RNA of the B2.1A-secreting hybridomas cells. The vH and vL segments
were linked via a nucleotide sequence encoding a flexible linker
(GGSGGSGGGGSGGGGSGGGAS) and this cassette placed downstream
from a Igk-leader sequence in a modified mammalian expression vector
pDisplay (Life Technologies) to generate a single-chain variable fragment
(scFv) expression construct. The vH-linker-vL cassette was subsequently
sub-cloned into pLOU3, an Escherichia coli expression vector derived from
the pMAL-c2x vector (NEB). The construct encodes a maltose-binding
protein (MBP)-B2.1 A scFv fusion protein, which carries a 6-histidine
sequence at its N-terminus and a tobacco etch virus (TEV) protease
cleavage site at the C-terminus of MBP. Briefly, the fusion protein was
expressed in E. coli strain Rosetta-gami 2(DE3)pLysS (EMD Millipore) and
the protein purified from cell extract using HisTrap and MBPTrap columns
(GE Healthcare). The protein was then digested with TEV protease and re-
applied to the HisTrap column. The unbound fraction containing B2.1 A
scFv was further purified on a 16/60 Sephacryl S100 (GE Healthcare) in PBS.
Crystallization of AP33 Fab complexed with B2.1 A scFv
A Crystal Gryphon Liquid Handling System (Art Robbins Instruments) was
used to set up co-crystallization trials using the sitting drop method. B2.1 A
scFv was buffer exchanged into crystallization buffer (20 mM Tris–HCl pH
8.5, 80 mM NaCl) and combined with AP33 Fab in a 1:1 molar ratio at a final
concentration of 5 mg/mL
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Data collection
Two datasets were obtained from a crystal grown under condition D4
(0.1 M sodium HEPES pH 7.5, 25% (w/v) PEG 8000) of the PEGs suite
(Qiagen). One low-resolution set (3 Å) was collected on a Rigaku-MSC
Micromax-007 X-ray generator and Saturn 944+ CCD detector at 100 K in-
house. The second high-resolution dataset (1.85 Å) was collected from the
same crystal at the Diamond Synchrotron facility, IO3 beamline on a
PILATUS 3 6M detector.
Structure determination and refinement
Molecular replacement using Phaser was used to determine the structure
from the low-resolution dataset60. Two ensembles were used for the
search structure: the AP33 structure (pdb 4gaj) and an in-silico model of
B2.1 A created by the SWISS-MODEL server. Three cycles of rigid body
refinement and several restrained refinement cycles were performed in
Phenix61. This low-resolution structure was used to model the high-
resolution dataset with the same space group selected with Pointless62.
Again this model was refined using rigid body refinement in Phenix then
alternating cycles of restrained refinement with TLS parameters and water
refinement with model inspection and manual refinement on Coot63.
Contact in the CCP4 suite and the PDBePISA server64 were used to analyze
inter- and intra-molecular interactions. Finally, MolProbity65 was used for
model validation which showed that 98% of residues were in favored
regions of the Ramachandran plot, with 0.15% in outlier regions, and a
Clashscore of 4.86. Pymol was used to generate all images.
Protein structure accession numbers
The coordinates and structure factors are deposited in the Protein Data
Bank under accession code 6SXI.
Affinity Measurements
SPR experiments were performed on a Biacore X100 instrument at 25 °C.
The proteins used were purified to homogeneity by affinity chromato-
graphy followed by SEC. AP33 IgG was immobilized on a CM5 chip by
standard amine coupling to a level of approximately 400 resonance units
(RU). A second flow cell on the same chip was activated and deactivated in
the absence of antibody as a negative control. Analytes (E2661 or B2.1 A
Fab) were injected over the chip at 30 µl/min in buffer (10mM HEPES pH
7.4, 150mM NaCl, 3 mM EDTA, 0.05% Tween 20), at concentrations ranging
from 0.6 to 80 nM. The sensor surface was regenerated between each cycle
with two 60 s injections of 10mM glycine pH 1.5. Each sensorgram was
corrected for nonspecific binding by subtraction of the signal obtained
from the negative control flow cell. The sensorgrams were analyzed using
Biacore X100 Evaluation software (BIAcore) by applying a 1:1 binding
model to obtain kinetic affinity constants.
Site-directed mutagenesis of B2.1 A ScFv
The BeAtMuSiC program66 and the SNP-IN tool (http://korkinlab.org/
snpintool/) were used to predict single point mutations that may enhance
the affinity of AP33 and B2.1 A. Site-directed mutagenesis was used to
generate mutations in the B2.1 A ScFv background. The proteins were
expressed in E.coli and purified using the His-tag on a BioSprint 15
workstation (Qiagen).
Hepatitis C virus production and titration
Plasmids encoding the BiCre-Con1 and BiCre-JC1 genomes67 were
linearized with XbaI then transcribed using T7 RiboMAXTM Express Large
Scale RNA Production System (Promega) and purified using RNeasy kit
(Qiagen). RNA was electroporated into Huh7.5 cells and infectious virus
was harvested every 3 h from 24 h to 96 h post-electroporation then
concentrated using a MilliporeSigma™ Amicon™ Bioseparations stirred cells
(Merck). Virus titers were determined in a focus-forming unit assay by serial
dilution on Huh7.5 cells. Infected cells were stained for the NS5A viral
protein as described previously68.
HCVcc neutralization assays
AP33 antibody neutralization assays were performed in the SEAP-reporter
cell line Huh7-J20 as described previously22. Briefly, cells were seeded at a
density of 4 × 103 cells per well into a 96-well plate and incubated at 37 °C
overnight prior to infection. Virus was preincubated for 1 h at 37 °C for with
AP33 prior to infection at a multiplicity of infection (MOI) of 0.1.
Engraftment of adult human hepatocytes in FNRG mice
Female FNRG mice69 between 8–12 weeks old of age were transplanted
with 0.5 × 106 of cryopreserved adult human hepatocytes (Donor 28 from
QPS, USA). Hepatocytes were injected by intrasplenic injection during
isoflurane anesthesia using an insulin syringe. The peritoneum was sutured
using 4.0 VICRYL sutures (Johnson & Johnson, USA) and skin was closed
using MikRon Autoclip surgical clips (Becton Dickinson, UK). To facilitate
the engraftment of adult human hepatocytes, mice were cycled off and on
with the drug nitisinone (Yecuris, USA) according to weight loss and health
state. Nitisinone was provided in the drinking water to FNRG mice for
maintenance from birth and was retired after surgery. Nitisinone was
added again after 10–15% body weight loss was reached. Once the body
weight loss was recovered, mice were provided with 10% Nitisinone
solution for 2 days before animals were put back on plain drinking water.
Human albumin ELISA
Human albumin ELISA was used to quantify the level of human hepatocyte
engraftment after surgery following a previously published protocol70.
Mice were bled from the tail vein and serum was serially diluted
before use.
Infection of engrafted FNRG mice after antibody treatment
FNRG mice highly engrafted with human adult hepatocytes according to
serum human albumin secretion (at least 1mg hAlb per mL in peripheral
blood) were selected to test the protective capacity of B2.1 A antibodies
against BiCreJc1 (genotype 2a) and BicreCon1 (genotype 1b) HCV viruses.
Mice were intraperitoneally injected 3 times with 80 μg per mouse of IgG
from mice immunized with B2.1 A Fab, or from mock-immunized mice. The
first injection was 24 h and the second was 1 h prior HCV infection, the third
was 24 h post-HCV infection. Mice were intravenously infected with 104
TCID50 of BicreCon1 or BiCreJc1 in PBS. To evaluate the level of infection
mice were bled through the tail vein at day 7, 21, and 35 post-infection.
Animal Ethics
All animal work with infectious agents was conducted in BSL3 facilities in
accordance with local rules at Imperial College London, UK. All animal
research described in this study was approved by appropriate local Ethics
Committee and carried out under United Kingdom Home Office Licenses in
accordance with the approved guidelines and under the Animals (Scientific
Procedures) Act 1986 (ASPA).
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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